Table 2.
MicroRNA expression in gliomas.
| MiRNA | Test | Expression alteration a | Fold change | Relevance to grading b | Relevance to prognosis c | References |
|---|---|---|---|---|---|---|
| Mir-7 | qRT-PCR | T(−), C(−) | [28] | |||
| MiR-10b | qRT-PCR | T(+), C(+) | 90.4 (tissues), 94.8 (U87), 18.4 (U251) | (+) | (−) | [32,33,34] |
| Mir-15b | MicroRNAarray, qRT-PCR | T(−), C(−) | 0.11 (tissues) | [36,37] | ||
| Mir-16-1 | qRT-PCR | C(−) | [38] | |||
| Mir-17 | qRT-PCR | T(+), C(+) | 2.7–5.6 (tissues) | (+) | (−) | [42] |
| Mir-17–92 cluster | qRT-PCR | T(+) | 1.5–5 (tissues) | (+) | [39] | |
| Mir-21 | qRT-PCR, In situ hybridization | T(+), C(+) | (+) | [21,45] | ||
| Mir-23b | qRT-PCR | T(+), C(+) | 7.48–16.04 (cell lines) | [61] | ||
| Mir-26a | MicroRNA array | T(+) | 6 (GBM tissues) | [62] | ||
| Mir-30e* | MicroRNA array, qRT-PCR | T(+), C(+) | (+) | (−) | [63] | |
| Mir-31 | qRT-PCR | T(−) | [64] | |||
| Mir-34a | qRT-PCR | T(−), C(−) | [157] | |||
| Mir-101 | qRT-PCR | T(−), C(−) | (−) | [67] | ||
| Mir-124 | qRT-PCR | T(−), C(−) | 57 (GBM tissues) | [23,68] | ||
| Mir-125b | Northern blotting, In situ localization, MicroRNA array, qRT-PCR | Glioblastoma-associated endothelial cells(−), ATRA-treated human glioma cell lines(−), CD133+ cells(−) | [69,70,71,72] | |||
| MiR-125b-2 | qRT-PCR | GBM tissues(+), cells treated with TMZ(+), CD133+(+) | [73] | |||
| Mir-128 | MicroRNA array, qRT-PCR | T(−), C(−) | (−) | [74,75,76] | ||
| Mir-137 | MicroRNA array, qRT-PCR | T(−), C(−) | (−) | [24] | ||
| Mir-145 | TCGA analysis, qRT-PCR, MicroRNA array | T(−), C(−) | <0.1 (cell lines) | (−) | (+) | [79,80,81,82] |
| Mir-146 | qRT-PCR | T(−), C(−) | [158,159] | |||
| Mir-152 | qRT-PCR | T(−), C(−) | 0.14 (tissues) | [36] | ||
| Mir-153 | qRT-PCR | T(−), C(−) | [84] | |||
| Mir-181 | qRT-PCR | T(−), C(−) | (−) | [86] | ||
| Mir-182 | qRT-PCR | T(+), C(+) | (+) | (−) | [160] | |
| Mir-184 | Stem-loop real-time RT-PCR | T(−) | 0.02–0.56 (tissues) | [89] | ||
| Mir-195 | qRT-PCR | T(−), C(−) | <0.6 (cell lines), <0.4 (tissues) | [91,92] | ||
| Mir-204 | qRT-PCR | T(−), C(−) | (+) | [93] | ||
| Mir-221/222 | qRT-PCR, MicroRNA array | T(+), C(+) | 2.74 (cell lines), 6.23 (tissues) | (+) | (−) | [101,102] |
| Mir-296 | qRT-PCR | C(+) | [104] | |||
| Mir-326 | qRT-PCR | T(−) | 0.15–0.18 (tissues) | (−) | (+) | [105,106,107] |
| Mir-410 | TCGA analysis, qRT-PCR | T(−), | [108] | |||
| Mir-451 | qRT-PCR, Fluorescent in situ hybridization | T(−), C(−) | (−) | [161,162] | ||
| Mir-455 | MicroRNA array | Cells resistant to TMZ(+) | [90] | |||
| Mir-486 | MicroRNA array, qRT-PCR | T(+), C(+) | (+) | (−) | [110] |
a T = Tumor tissues, C = glioma cell lines, (+) = overexpression, (−) = downregulation; b (+) = Higher WHO grade with higher expression, (−) = higher WHO grade with lower expression; c (+) = Shorter survival with higher expression, (−) = longer survival with higher expression.